Introduction
Watch renowned clinical specialists in lung cancer discuss the latest developments in NSCLC with MET exon 14 skipping alterations with our touchPANEL DISCUSSION from the European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona, 27 September–1 October 2019, and consider what the findings may mean for your own clinical practice.
Prof. David Planchard chairs a discussion with Prof. Enriqueta Felip and Prof. Frank Griesinger on recent data and issues surrounding the use of MET inhibitors in NSCLC with MET exon 14 skipping mutations.
This activity is intended for oncologists and healthcare professionals outside the USA.
This touchPANEL DISCUSSION was recorded in October 2019.
Learning Objectives
After watching this touchPANEL DISCUSSION, you should be able to:
-
Recognize unmet needs for patients with METex14+ NSCLC, including practical considerations for all members of the multidisciplinary team in order to achieve prompt and effective mutation testing and corresponding treatment initiation
-
Describe the evolving therapeutic landscape and emerging clinical trial data in METex14+ NSCLC and potential impact in your own country
-
Identify eligibility criteria and patients appropriate for referral to ongoing clinical trials investigating METex14+ NSCLC
Clinical Spotlight
-
The potential of MET inhibitors in clinical practice for MET‑altered NSCLC
-
Data for tepotinib, capmatinib, crizotinib and savolitinib in METex14+ NSCLC
-
Current status and future promise of liquid biopsy for earlier identification of METex14+ NSCLC
Clinical Spotlight
-
The potential of MET inhibitors in clinical practice for MET‑altered NSCLC
-
Data for tepotinib, capmatinib, crizotinib and savolitinib in METex14+ NSCLC
-
Current status and future promise of liquid biopsy for earlier identification of METex14+ NSCLC
The Expert Panel
PROF. DAVID PLANCHARD
David Planchard is Associate Professor of Medicine, Thoracic Tumour Board, at the Institut Gustave Roussy, Villejuif, France. Prof. Planchard leads clinical trials in thoracic diseases for the tumour board, and his contribution has enabled the thoracic tumour group to build a long-term clinical research strategy based on molecular screening.
Disclosures: Consultant/Advisory Board positions with AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, MedImmune, Merck, Novartis, Peer CME, Pfizer, prIME Oncology and Roche.
PROF. ENRIQUETA FELIP
Enriqueta Felip is the Head of Division in the Medical Oncology Department and Head of the Thoracic Cancer Group at Vall d’Hebron University Hospital and Institute of Oncology, Barcelona, Spain. She is in charge of thoracic malignancy management and is responsible for thoracic cancer trials undertaken by the Oncology Department.
Disclosures: Prof. Felip has been an advisor or speakers’ bureau member for: AbbVie, AstraZeneca, BerGenBio, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, priME Oncology, Roche, Samsung, Takeda and Touchtime. She has been an independent Board member of Grifols and has received research funding from Fundación Merck Salud, Grant for Oncology Innovation EMD Serono.
PROF. FRANK GRIESINGER
Frank Griesinger is the Director of the Department of Haematology and Oncology at the Pius-Hospital, Oldenburg, lecturer at the University of Göttingen, Germany, and holds a Professorship in Oncology at the University of Oldenburg, Germany. He is currently involved in introducing molecular stratified treatments in lung cancer in Germany and in preparing the guidelines of the German Society of Haematology and Oncology for the treatment of NSCLC.
Disclosures: Prof. Griesinger has disclosures from the following companies: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Lilly, Medac, Merck, MSD, Novartis, Pfizer, Roche and Takeda.
About This Activity
Activity Description and Learning Objectives
In this activity, experts in NSCLC discuss the latest developments in NSCLC with MET exon 14 skipping alterations. This activity was recorded at the European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona 27 September–1 October 2019.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
After watching this activity, participants should be able to:
-
Recognize unmet needs for patients with METex14+ NSCLC, including practical considerations for all members of the multidisciplinary team in order to achieve prompt and effective mutation testing and corresponding treatment initiation
-
Describe the evolving therapeutic landscape and emerging clinical trial data in METex14+ NSCLC and potential impact in your own country
-
Identify eligibility criteria and patients appropriate for referral to ongoing clinical trials investigating METex14+ NSCLC
Target Audience
This activity has been designed to meet the educational needs of oncologists, nurse specialists, pathologists and other allied healthcare professionals involved in the management of NSCLC.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Prof. David Planchard discloses Consultant/Advisory Board positions with AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, MedImmune, Merck, Novartis, Peer CME, Pfizer, prIME Oncology and Roche.
Prof. Enriqueta Felip has disclosures from the following companies AbbVie, AstraZeneca, BerGenBio, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, priME Oncology, Roche, Samsung, Takeda and touchIME. She has been an independent Board member of Grifols and has received research funding from Fundación Merck Salud, Grant for Oncology Innovation EMD Serono.
Prof. Frank Griesinger has disclosures from the following companies: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Lilly, Medac, Merck, MSD, Novartis, Pfizer, Roche and Takeda.
Content Reviewer
Walter Murray Yarbrough, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Martin Quinn has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: October 22, 2019. Date credits expire: October 22, 2020.
touchCONGRESS Expert Interviews
Hear renowned clinical specialists in lung cancer give their opinions on the latest developments in NSCLC with MET exon 14 skipping alterations with our touchCONGRESS Expert Interviews from the European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona, 27 September – 1 October 2019
